Investment Thesis
Autonomix Medical is a pre-revenue medical device company with zero revenue and significant ongoing cash burn of $9.4M annually, indicating the company has not yet achieved commercial traction. With only $9.9M in cash and negative operating cash flow, the company has approximately 12 months of runway before potential capital depletion, absent additional funding or a major inflection in commercialization.
Strengths
- Strong current ratio of 6.18x indicates short-term liquidity to meet near-term obligations
- Conservative balance sheet with low debt-to-equity ratio of 0.17x minimizes financial leverage risk
- Minimal capital expenditure of $7K suggests asset-light business model focused on development rather than infrastructure
Risks
- Zero revenue despite being a publicly traded company indicates inability to commercialize product or gain market adoption
- Negative operating cash flow of -$9.4M combined with $9.9M cash balance creates imminent funding requirement within 12 months
- Massive negative returns on equity (-164.1%) and assets (-137.6%) demonstrate value destruction and failed product-market fit
- No insider activity in past 90 days suggests lack of management confidence and potential disengagement
- Complete absence of gross profit prevents assessment of unit economics and operational viability
Key Metrics to Watch
- Revenue recognition and commercial traction milestones
- Cash burn rate and remaining runway before funding requirement
- Operating cash flow improvement trajectory and path to breakeven
Financial Metrics
Revenue
0.0
Net Income
-14.0M
EPS (Diluted)
$-0.74
Free Cash Flow
-9.4M
Total Assets
10.2M
Cash
9.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-164.1%
ROA
-137.6%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
6.18x
Quick Ratio
6.18x
Debt/Equity
0.17x
Debt/Assets
16.2%
Interest Coverage
-142.97x
Long-term Debt
1.5M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-19T18:08:46.251074 |
Data as of: 2025-12-31 |
Powered by Claude AI